.jpg)
.png)
Last Updated: Tuesday, 09-Jun-2020 19:15:00 EDT
Denver-area clinical pharmacist assumes role during NLA virtual business meeting
JACKSONVILLE, Fla. — Joseph J. Saseen, PharmD, CLS, FNLA, officially assumed the role of National Lipid Association (NLA) President at the NLA’s annual virtual business meeting on Monday, June 8, 2020 after serving for the past year as President-Elect. He succeeds Houston-based lipidologist Antonio M. Gotto, MD, DPhil, FNLA, who will be the NLA’s Immediate Past President.
Last Updated: Tuesday, 09-Jun-2020 18:45:00 EDT
Esperion has announced that NEXLIZET™ (bempedoic acid and ezetimibe) Is now available in pharmacies in the United States. NEXLIZET™ is an oral, once-daily, fixed-dose combination tablet indicated as an adjunct to diet and maximally tolerated statin for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C.
Last Updated: Tuesday, 02-Jun-2020 12:30:00 EDT
|
Last Updated: Friday, 29-May-2020 15:30:00 EDT
Register for the NLA Annual Business Meeting by clicking here.
Join us on Monday, June 8 from 6:00 – 6:30 PM ET for the NLA’s Annual Business Meeting for important NLA updates and award announcements:
Last Updated: Thursday, 21-May-2020 21:00:00 EDT
Last Updated: Wednesday, 22-Apr-2020 21:15:00 EDT
View the April 2020 Midwest quarterly e-newsletter by clicking here.
Last Updated: Wednesday, 01-Apr-2020 16:15:00 EDT
View the April 2020 Pacific quarterly e-newsletter by clicking here.
Last Updated: Wednesday, 01-Apr-2020 00:00:00 EDT
Esperion has announced that NEXLETOL™ (bempedoic acid) is now available in pharmacies in the United States. NEXLETOL is an oral, once-daily, tablet indicated as an adjunct to diet and maximally tolerated statin for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C.
Last Updated: Monday, 30-Mar-2020 13:15:00 EDT
The NLA aims to provide its members with relevant information and tools to succeed in the frequently changing healthcare landscape. View the documents below for resources provided by NLA members. Check back later to view new resources.
In 2019, the Centers for Disease Control and Prevention reported that prevalence for both obesity and overweight have continued to rise over the last eight years and are at an all-time high for adults and adolescents.(1) Approximately two-thirds of US adults are either obese (31%) or overweight (35%). Approximately one-third of US adolescents in grades 9-12 are obese (15%) or overweight (16%).
Article By:
KEVIN C. MAKI, PhD, CLS, FACN, FNLA
Department of Applied Health Science
School of Public Health
Indiana University
Bloomington, IN
Midwest Biomedical Research
Addison, IL
MARY R. DICKLIN, PhD
Midwest Biomedical Research Addison, IL
MAYA BALAKRISHNAN, MD
Section of Gastroenterology & Hepatology Baylor College of Medicine
Houston, TX
DAVID R. NEFF, DO
Past President, Midwest Lipid Association Michigan State University
College of Osteopathic Medicine Associate Clinical Professor Department of Family & Community Medicine
Ingham Regional Medical Center Lansing, MI